Larosuzet
Products and Business Services
Information
Larosuzet integrates the strengths of ezetimibe, an intestinal cholesterol absorption inhibitor, and rosuvastatin, an HMG-CoA reductase inhibitor, to achieve optimal lipid control. This dual-action formula reduces LDL-C and total cholesterol levels more effectively than either agent alone. Larosuzet is suitable for treating hypercholesterolemia and mixed dyslipidemia, providing a balanced and efficient approach to cardiovascular risk reduction. Available in various fixed-dose combinations, including 10/10 mg, 10/20 mg, and 10/40 mg (ezetimibe/rosuvastatin)
Distribution Areas
AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied From
Egypt
Main Categories
Finished Dosage Forms
